129
Views
19
CrossRef citations to date
0
Altmetric
Review

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

, , , , , , , , & show all
Pages 2047-2063 | Published online: 05 Jul 2017

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.